Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 May 2014Website:
http://www.theravance.comNext earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 17:05:31 GMTDividend
Analysts recommendations
Institutional Ownership
TBPH Latest News
Here, we discuss some reasons why investing in Theravance (TBPH) stock now may turn out to be a prudent move.
Theravance (TBPH) exceeds earnings expectations in the first quarter of 2024, with revenues also meeting expectations.
Theravance Biopharma (TBPH) reported a quarterly loss of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.19. This is an improvement from a loss of $0.24 per share in the same quarter last year.
Theravance Biopharma, Inc. (NASDAQ: TBPH) is set to announce its financial results for the first quarter of 2024 and give a business update on Monday, May 13, 2024, after the market closes. A conference call and webcast will follow at 5:00 pm ET (2:00 pm PT/10:00 pm IST) on the same day.
Theravance Bio (TBPH) experienced a significant increase in its stock price in the last trading session, with trading volume above usual levels. Despite recent adjustments to earnings estimates, it is uncertain if this will lead to additional price gains in the short term.
Theravance's (TBPH) fourth-quarter earnings and revenues beat estimates. The company achieves profitability on an adjusted basis during the same time.
Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript
Theravance Biopharma (TBPH) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.21 per share a year ago.
The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Theravance Biopharma shares fell more than 20% after the company reported that its therapeutic for chronic obstructive pulmonary disease (COPD), a common lung disease, failed a clinical trial. Its stock was down 20.7% at US$9.14 before Friday's opening bell.
- 1(current)
What type of business is Theravance Biopharma?
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
What sector is Theravance Biopharma in?
Theravance Biopharma is in the Healthcare sector
What industry is Theravance Biopharma in?
Theravance Biopharma is in the Biotechnology industry
What country is Theravance Biopharma from?
Theravance Biopharma is headquartered in United States
When did Theravance Biopharma go public?
Theravance Biopharma initial public offering (IPO) was on 16 May 2014
What is Theravance Biopharma website?
https://www.theravance.com
Is Theravance Biopharma in the S&P 500?
No, Theravance Biopharma is not included in the S&P 500 index
Is Theravance Biopharma in the NASDAQ 100?
No, Theravance Biopharma is not included in the NASDAQ 100 index
Is Theravance Biopharma in the Dow Jones?
No, Theravance Biopharma is not included in the Dow Jones index
When does Theravance Biopharma report earnings?
The next expected earnings date for Theravance Biopharma is 07 August 2024